Epiodyne

Epiodyne, Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative drugs derived from novel chemical matter and targeting delta opioid receptors. Founded in 2016, the company employs quantitative pharmacological and behavioral methodologies to translate its research insights into new therapeutic options. Epiodyne specializes in creating analgesics aimed at addressing neurobehavioral symptoms associated with brain disorders. By targeting the brain's opioid peptide system, Epiodyne seeks to restore the function of the brain's reward system, providing effective treatments for conditions such as compulsivity, self-injury, and addiction.